Creso Pharma commences sales of cannaQIX® 50 Medicinal Cannabis in Australia
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH | FRA:1X8) has commenced sales of its flagship medicinal cannabis product cannaQIX® 50 to Burleigh Heads Cannabis, one of Australia’s leading medicinal cannabis distribution companies.
Burleigh Heads Cannabis has confirmed prescriptions are already taking place and the product is receiving very positive feedback from physicians and patients.
Creso Pharma and Burleigh Heads Cannabis have placed initial focus on introducing cannaQIX® 50, which is now being sold in Australia as a therapeutic product via approved channels as ‘LozaCan’.
cannaQIX® 50/LozaCan has been developed to Good Manufacturing Practice (GMP) standards and is produced in Switzerland by Creso Pharma’s partner, Switzerland-based food and pharma development company Domaco, Dr. med Aufdermaur AG to the highest Swiss quality with a ‘Swiss Made’ label.
Creso Pharma and Burleigh Heads Cannabis are exploring the potential to expand their collaboration to include additional therapeutic/medicinal cannabis products from Creso Pharma’s pipeline.
Fast working treatment for chronic pain
cannaQIX 50® is Creso Pharma’s proprietary buccally formulated cannabidiol (CBD) lozenge which is designed to support the management of chronic pain.
Each cannaQIX 50® lozenge contains 50mg of CBD from full spectrum hemp plant extracts along with niacin, vitamins B6, B12, C, and zinc in a standardised pharma-grade formulation produced in Switzerland.
cannaQIX 50® comes in packs of 30 lozenges in a proprietary delivery formulation designed for buccal absorption and to dissolve in the mouth.
This method works faster and more efficiently than tablets or capsules which need to be swallowed and have a high percentage of their ingredients broken down when absorbed through the intestine and passed first through the liver.
By being dissolved in the mouth, the active ingredients enter the bloodstream directly, avoiding this first pass through the liver. cannaQIX 50® lozenges taste great and are a patient-friendly way to administer precise doses of CBD when compared to oil-based alternatives.
Extension of exclusive distribution agreement
The delivery follows the recent signing of an exclusive Distribution Agreement with Burleigh Heads Cannabis in April, and the securing of an import permit for Australia.
The collaboration will enable Creso Pharma to leverage Burleigh Heads Cannabis and CDA’s local regulatory experience and established distribution networks to facilitate patient access to its products in Australia.
Burleigh Heads Cannabis is a subsidiary of CDA Health Pty Ltd, an established Australian business supporting patient access to medical cannabis products in Australia.
Through its affordable CDA-branded products and CDA Clinics, the group assists doctors and patients in navigating the process of applying, prescribing and sourcing medical cannabis legally, while also providing educational resources and one-to-one services from their consultant doctors through physical and telehealth clinics.
CDA has completed over 5000 successful Therapeutic Goods Administration (TGA) patient approvals since launching in October 2018.
Discussing this milestone event and pointing to its significance in terms of new product launches, Dr Miri Halperin Wernli, Creso Pharma’s chief executive and co-founder said, “We are pleased to announce the first delivery of cannaQIX® 50 in Australia.
‘’Burleigh Heads Cannabis and CDA Clinics Australia continue to rapidly expand their patient reach with their extensive distribution network.
‘’This close partnership enables us to fulfil our mission of bringing life-improving products to patients in Australia.
‘’We’re delighted to announce this progress and look forward to further new product introductions in the near future.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.